Beta-Blocker Therapy on Blood Pressure in Subclinical Hyperthyroidism: A Retrospective Observational Study

Basit Öğe Kaydı
dc.contributor.authorKeskin Kaplan, Aşkın
dc.contributor.authorSezgin, Yılmaz
dc.date.accessioned2024-07-12T22:04:25Z
dc.date.available2024-07-12T22:04:25Z
dc.date.issued2023en_US
dc.description.abstractThis study aimed to investigate the effect of beta- blocker therapy on blood pressure in patients with subclinical hyperthyroidism and to elucidate the potential benefits of this treatment approach. This retrospective observational cohort study included 56 hypertensive patients with subclinical hyperthyroidism who received beta-blocker therapy. Patient data, including demographic characteristics, thyroid function tests, and blood pressure measurements, were collected from medical records and evaluated using statistical analysis with SPSS Statistics software. The cohort of hypertensive patients included 35 patients with uncontrolled blood pressure and 21 newly diagnosed patients, with a total average age of 55 and 73.2% of them being female. In newly diagnosed and uncontrolled hypertensive patients, TSH levels were below the average, and T3 levels were high (p<0.001). Significant reductions in systolic and diastolic blood pressure were observed in both groups after beta- blocker therapy (p<0.001). The most significant decrease in blood pressure in beta-blocker therapy occurred in newly diagnosed hypertensive patients, with an average decrease of 37.85 mmHg. Additionally, a significant reduction in the number of antihypertensive medications was observed in patients receiving beta-blocker therapy (p<0.001). In conclusion, our study demonstrates the positive effects of beta-blocker therapy on blood pressure control in patients with subclinical hyperthyroidism. Particularly, the significant decrease in blood pressure in newly diagnosed hypertensive patients indicates the potential of beta-blockers as a preferred treatment option. This study highlights the necessity of a causal approach in treating hypertension with thyroid disorders. However, considering the limitations of the study design, further comprehensive research is needed to confirm these findings.en_US
dc.identifier.doi10.37989/gumussagbil.1324955
dc.identifier.endpage901en_US
dc.identifier.issn2146-9954
dc.identifier.issue3en_US
dc.identifier.startpage895en_US
dc.identifier.trdizinid1199757en_US
dc.identifier.urihttps://doi.org/10.37989/gumussagbil.1324955
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1199757
dc.identifier.urihttps://hdl.handle.net/20.500.12415/9747
dc.identifier.volume12en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofGümüşhane Üniversitesi Sağlık Bilimleri Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY05139
dc.titleBeta-Blocker Therapy on Blood Pressure in Subclinical Hyperthyroidism: A Retrospective Observational Studyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu